| Source: |
| Type: |
| Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body. |
| - | in-vitro, | Pca, | pCSCs |
| 53- | QC, | Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | NA, | MDA-MB-468 |
| 96- | QC, | docx, | Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 88- | QC, | PacT, | Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production |
| - | vitro+vivo, | Pca, | PC3 |
| 85- | QC, | Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3) |
| - | in-vitro, | Pca, | PC3 |
| 82- | QC, | ATG, | Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 156- | Ralox, | Tam, | GEN, | CUR, | Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2441- | RES, | Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions |
| - | Review, | Var, | NA |
| 3086- | RES, | Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 3089- | RES, | The Role of Resveratrol in Cancer Therapy |
| - | Review, | Var, | NA |
| 3095- | RES, | Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk |
| - | in-vitro, | BC, | NA |
| 3072- | RES, | Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 3070- | RES, | Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma |
| - | in-vitro, | RCC, | ACHN | - | in-vitro, | RCC, | 786-O | - | in-vivo, | NA, | NA |
| 2988- | RES, | The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation |
| - | in-vitro, | HCC, | HUH7 |
| 1747- | RosA, | Molecular Pathways of Rosmarinic Acid Anticancer Activity in Triple-Negative Breast Cancer Cells: A Literature Review |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MDA-MB-468 |
| 3016- | RosA, | Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling |
| - | in-vitro, | HNSCC, | UM-SCC-6 | - | in-vitro, | HNSCC, | UM-SCC-10B |
| 3027- | RosA, | Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | HCC, | SMMC-7721 cell |
| 3008- | RosA, | Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells |
| - | in-vitro, | Melanoma, | SK-MEL-28 |
| 3035- | RosA, | Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling |
| - | in-vitro, | PC, | NA | - | in-vivo, | NA, | NA |
| 1048- | RosA, | GSL, | Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis |
| - | in-vivo, | Colon, | MC38 |
| 7375- | RS, | Regulation of hippo signaling mediated apoptosis by Rauvolfia tetraphylla in triple-negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1132- | RT, | Rutin Promotes Proliferation and Orchestrates Epithelial–Mesenchymal Transition and Angiogenesis in MCF-7 and MDA-MB-231 Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| - | in-vivo, | CRC, | Caco-2 | - | vitro+vivo, | CRC, | CX-1 |
| 5127- | Sal, | Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway |
| - | in-vitro, | Ovarian, | NA |
| 1209- | SANG, | Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration |
| - | in-vitro, | Lung, | A549 |
| 6446- | SAO, | Alpha-Santalol, a Component of Sandalwood Oil Inhibits Migration of Breast Cancer Cells by Targeting the β-catenin Pathway |
| - | in-vitro, | BC, | NA |
| 6440- | SAO, | Biological Properties of Sandalwood Oil and Microbial Synthesis of Its Major Sesquiterpenoids |
| - | Review, | Var, | NA |
| 5139- | SAS, | Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | U2OS |
| 9278- | SES, SSM, | Antitumor Effects of Sesamin via the LincRNA-p21/STAT3 Axis in Human Bladder Cancer: Inhibition of Metastatic Progression and Enhanced Chemosensitivity |
| - | vitro+vivo, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 3198- | SFN, | Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells |
| - | in-vitro, | Pca, | NA |
| 2166- | SFN, | Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction |
| - | in-vitro, | Oral, | NA | - | in-vivo, | NA, | NA |
| 1136- | SFN, | Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells |
| - | in-vitro, | Lung, | NA | - | in-vivo, | NA, | NA |
| 111- | SFN, | Sulforaphene Interferes with Human Breast Cancer Cell Migration and Invasion through Inhibition of Hedgehog Signaling |
| - | in-vitro, | BC, | SUM159 |
| 1466- | SFN, | Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway |
| - | vitro+vivo, | Thyroid, | FTC-133 |
| 1462- | SFN, | Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 1499- | SFN, | Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway |
| - | in-vitro, | BC, | NA |
| 3306- | SIL, | Rad, | Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation |
| - | Review, | Var, | NA |
| 3296- | SIL, | Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vivo, | Oral, | YD10B |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | Var, | NA |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 3330- | SIL, | Mechanistic Insights into the Pharmacological Significance of Silymarin |
| - | Review, | Var, | NA |
| 3326- | SIL, | Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B |
| 1276- | SIL, | Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells |
| - | in-vitro, | BC, | NA | - | in-vitro, | Thyroid, | NA |
| 1127- | SIL, | Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1 |
| - | in-vitro, | Lung, | A549 |
| 2417- | SK, | Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H446 |
| 2360- | SK, | Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway |
| - | in-vitro, | NPC, | HONE1 | - | in-vitro, | NPC, | SUNE-1 |
| 2355- | SK, | Pharmacological properties and derivatives of shikonin-A review in recent years |
| - | Review, | Var, | NA |
| 2232- | SK, | Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis |
| - | in-vitro, | ESCC, | EC9706 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:326 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid